The stock's fall snapped a three-day winning streak.

Vertex Pharmaceuticals Inc. closed 13.15% short of its 52-week high of $519.88, which the company reached on November 8th.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

THOU DOTH PORTEST — Protests are set to pop up around the Bay State this weekend, capping off a week of tension between the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As a company, Vertex says, “We strike at the core of serious diseases to change people’s lives. Bringing together the ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

Story June 11 - Vertex Pharmaceuticals: Vertex is trimming ... while also closing most of its lab and office facilities. Story May 8 - Insitro: The South San Francisco-based biotech is shrinking ...

Worldwide Healthcare Trust PLC - Annual Financial Report PR Newswire LONDON, United Kingdom, June 11 10 June 2025Worldwide Healthcare Trust PLC(the "Company") Annual Financial ...

Nasdaq provides Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluation. Financial analysts and individual investors use PE Ratio and PEG ratios to determine the financial ...